Gilead Sciences Inc.
Gilead Sciences Reports Voting Results from 2025 Annual Meeting
Summary
Gilead Sciences, Inc. held its 2025 annual meeting on May 7, 2025, where shareholders elected nine directors, ratified the selection of Ernst & Young LLP as the independent registered public accounting firm, approved the compensation of Named Executive Officers on an advisory basis, and rejected several stockholder proposals. The meeting was well-attended with a significant number of shares represented. Financial statements and exhibits were furnished as part of the filing.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement